Answers are grounded in this paper and cite their sources.
Thrombocytopenia, characterized by a platelet count of less than 150×10⁹/L, is a frequent haematologic complication in individuals with solid cancers. It can result from various factors, including bone marrow metastasis, chemotherapy, radiation therapy, or immune-related platelet destruction. This review examines the origins, clinical consequences, and treatment approaches for thrombocytopenia in solid tumor patients, highlighting its prognostic significance and management difficulties.
No takes yet. Share an insight, caveat, or question.
A Nazim (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: